🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

382 results for “Ology” Clear

  1. SALINE, OTHER PLASMA PROTEIN FRACTIONS , Octaplasma 45-70 mg/ml pulver og væske til infusjonsvæske, oppløsning, Saline (NaCl)

    Wuhan Createrna Science and Technology Co., Ltd

    Early symptomatic phase Alzheimer's disease

    phase 2 small molecule active

    1 trial

  2. SELPERCATINIB, SELPERCATINIB

    Wuhan Createrna Science and Technology Co., Ltd

    Male or female patients age 12 years or older with a locally advanced or metastatic solid tumor with evidence of a RET gene alteration in tumor and/or blood.

    phase 2 small molecule active

    1 trial

  3. SELPERCATINIB, Selpercatinib, Selpercatinib, SELPERCATINIB, Selpercatinib

    Wuhan Createrna Science and Technology Co., Ltd

    Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors

    phase 2 small molecule active

    1 trial

  4. SRF388

    Coherus Oncology

    Hepatocellular Carcinoma

    phase 2 small molecule completed

    1 trial

  5. STC-15 in combination with toripalimab

    Coherus Oncology

    Solid Tumor

    phase 2 other active

    1 trial

  6. SUL-238, Identical to test product except without active substance

    Sana Biotechnology

    Parkinson’s Disease

    phase 2 small molecule active

    1 trial

  7. Sotrovimab

    Vir Biotechnology

    COVID-19

    phase 2 mab terminated

    1 trial

  8. Sotrovimab (Gen1)

    Vir Biotechnology

    Covid19

    phase 2 mab completed

    1 trial

  9. TD001

    Wuhan Createrna Science and Technology Co., Ltd

    Metastatic castration-resistant prostate cancer

    phase 2 small molecule active

    1 trial

  10. TNG908, TNG908, TNG908, TNG908, MIDAZOLAM

    Tango Therapeutics

    "Ph1: •Locally advanced (LA) or metastatic MTAP-deleted (met.MTAP-del.) solid tumors •MTAP-del.relapsed or refrac. Grade 4 astrocytoma or glioblastoma multiforme (R/R GBM) Ph2: A1:LA or met.MTAP-del. squamous and nonsquamous NSCLC A2:LA or met.MTAP-del. mesothelioma A3:LA or met.MTAP-del. sarcoma A4:LA or met.MTAP-del. pancreatic ductal adenocarcinoma or adenosquamous carcinoma w/predominantly adenocarcinoma histology A5:Other LA or met.MTAP-del. solid tumors A6:MTAP-del. R/R GBM"

    phase 2 small molecule active

    1 trial

  11. TREDIMIN 25.000 U.I. /2,5 ml soluzione orale

    Sana Biotechnology

    haematologic condition who need staminal cells transplant

    phase 2 small molecule active

    1 trial

  12. TRIPTORELIN, GONAPEPTYL 3,75 mg, poudre et solvant pour suspension injectable à libération prolongée en seringues pré-remplies., LEUPRORELIN ACETATE, BAY 1841788, TRIPTORELIN, DEGARELIX, LEUPRORELIN ACETATE, TRIPTORELIN, GOSERELIN ACETATE, LEUPRORELIN ACETATE, LEUPRORELIN ACETATE, TRIPTORELIN, GOSERELIN ACETATE, LEUPRORELIN ACETATE, DEGARELIX, LEUPRORELIN ACETATE

    The George Institute

    Adult patients with intermediate unfavorable risk prostate cancer as per NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines Prostate Cancer. Version 2.2021)

    phase 2 small molecule active

    1 trial

  13. Tecentriq 1 200 mg concentrate for solution for infusion

    Wuhan Createrna Science and Technology Co., Ltd

    Limited disease small-cell lung cancer

    phase 2 small molecule active

    1 trial

  14. Temozolomide

    PUMA BIOTECHNOLOGY, INC.

    Glioblastoma

    phase 2 small molecule active

    1 trial

  15. Temsirolimus

    PUMA BIOTECHNOLOGY, INC.

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  16. Tenofovir Alafenamide

    Vir Biotechnology

    Chronic Hepatitis B

    phase 2 small molecule completed

    1 trial

  17. Tipifarnib

    Kura Oncology

    Relapsed or Refractory Peripheral T-Cell Lymphoma

    phase 2 small molecule completed

    1 trial

  18. Tipifarnib

    Kura Oncology

    Myelodysplastic Syndromes

    phase 2 small molecule terminated

    1 trial

  19. Tipifarnib

    Kura Oncology

    Leukemia, Myelomonocytic, Chronic

    phase 2 small molecule completed

    1 trial

  20. Tipifarnib

    Kura Oncology

    HNSCC

    phase 2 small molecule completed

    1 trial

  21. Tipifarnib

    Kura Oncology

    HRAS Gene Mutation

    phase 2 small molecule completed

    1 trial

  22. Tipifarnib

    Kura Oncology

    Thyroid Cancer

    phase 2 small molecule completed

    1 trial

  23. Toripalimab

    Coherus Oncology

    Sinonasal Cancer

    phase 2 small molecule active

    1 trial

  24. Toripalimab

    Coherus Oncology

    Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources